{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:40:53Z","timestamp":1786326053318,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL131831"],"award-info":[{"award-number":["R01HL131831"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.cardfail.2020.04.011","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T11:30:51Z","timestamp":1590406251000},"page":"769-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Sacubitril\/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling"],"prefix":"10.1016","volume":"26","author":[{"given":"Kelly","family":"Tam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Aronovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchita","family":"Pande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Z.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Blanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2020.04.011_bib0001","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0002","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0003","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/2150135119825599","article-title":"Early experience with sacubitril\/valsartan in adult patients with congenital heart disease","volume":"10","author":"Lluri","year":"2019","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0004","first-page":"1569","article-title":"Sacubitril\/valsartan: beyond natriuretic peptides","volume":"103","author":"Singh","year":"2017","journal-title":"Heart (British Cardiac Society)"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrcardio.2014.64","article-title":"Natriuretic peptides in cardiometabolic regulation and disease","volume":"11","author":"Zois","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0006","first-page":"655","article-title":"Cardioprotective effects of LCZ696 (sacubitril\/valsartan) after experimental acute myocardial infarction","volume":"2","author":"Ishii","year":"2017","journal-title":"JACC Basic Trans Sci"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0007","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/CIRCHEARTFAILURE.113.000575","article-title":"Protein kinase G I and heart failure: shifting focus from vascular unloading to direct myocardial antiremodeling effects","volume":"6","author":"Kong","year":"2013","journal-title":"Circulation Heart Fail"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0008","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0009","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cardfail.2017.12.010","article-title":"LCZ696 (sacubitril\/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease","volume":"24","author":"Suematsu","year":"2018","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejps.2018.11.037","article-title":"Sacubitril\/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation","volume":"128","author":"Mochel","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005565","article-title":"Sacubitril\/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts","volume":"12","author":"Burke","year":"2019","journal-title":"Circulation Heart Fail"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0012","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1073\/pnas.0802128105","article-title":"High blood pressure arising from a defect in vascular function","volume":"105","author":"Michael","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.003731","article-title":"Protein kinase G Ialpha inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo","volume":"1","author":"Blanton","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0014","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1038\/s41598-019-42209-7","article-title":"Distinct phenotypes induced by three degrees of transverse aortic constriction in mice","volume":"9","author":"Richards","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0015","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1038\/ncomms9482","article-title":"Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice","volume":"6","author":"Thoonen","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0016","doi-asserted-by":"crossref","first-page":"12925","DOI":"10.1073\/pnas.1414364111","article-title":"Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis","volume":"111","author":"Patrucco","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0017","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/CIRCRESAHA.116.310069","article-title":"Phosphodiesterase 2 protects against catecholamine-induced arrhythmia and preserves contractile function after myocardial infarction","volume":"120","author":"Vettel","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0018","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCHEARTFAILURE.115.002308","article-title":"Molecular screen identifies cardiac myosin-binding protein-C as a protein kinase G-Ialpha substrate","volume":"8","author":"Thoonen","year":"2015","journal-title":"Circulation Heart Fail"},{"key":"10.1016\/j.cardfail.2020.04.011_bib0019","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/gerona\/glt042","article-title":"Mutation of the protein kinase I alpha leucine zipper domain produces hypertension and progressive left ventricular hypertrophy: a novel mouse model of age-dependent hypertensive heart disease","volume":"68","author":"Blanton","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916419315878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916419315878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:43:24Z","timestamp":1761029004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916419315878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1071916419315878"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2020.04.011","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacubitril\/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2020.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}